On February 16-18, 2005, a joint meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the FDA Drug Safety Committee (“committee”) was convened to review the safety of  COX-2 inhibitors   including rofecoxib (Vioxx), celecoxib (Celebrex), and valdecoxib (Bextra). The committees reviewed the details of research studies and specifically evaluated the risks of these drugs in regard to heart attack and stroke. They also reviewed other antiinflammatory drugs including naproxen.